Citations

Showing 10 of 108152 citations.

High-Resolution Esophageal Manometry in the Inpatient Setting: A Tertiary Referral Center Experience
Antunes, Catiele , Zhou, Elinor, Assis, Daniella, Gutierrez, Olaya I. Brewer , Fain, Christopher, Sloan, Joshua A. , Sloan, Joshua A , AbiMansour, Jad P. , Stein, Ellen M.

Mayo Clinic

Foregut: The Journal of the American Foregut Society | July 23, 2021 | Volume: 1 | Issue: 3 | Pages: 296-299

10.1177/26345161211035119 Get It

High-resolution esophageal manometry (HRM) is frequently used in the outpatient setting, but its role in the inpatient setting is unknown. We conducted a retrospective study of patients who underwent inpatient or outpatient HRM. Few differences were noted between groups and 28% of inpatients had an additional intervention. Tolerance of oral diet and diabetes were associated with a lower likelihood of additional intervention. Ultimately, the inpatient HRM group had unique characteristics and few subsequent interventions.
Predictive modeling of spread in adult‐onset isolated dystonia: Key properties and effect of tremor inclusion
Wang, Meng , Morgante, Francesca , Adler, Charles H. , Bäumer, Tobias , Berardelli, Alfredo , Blumin, Joel H. , Borsche, Max , Brashear, Allison , Deik, Andres , Duque, Kevin R. , Feuerstein, Jeanne , Fox, Susan H. , LeDoux, Mark S. , Leegwater‐Kim, Julie, Mahajan, Abhimanyu , Ondo, William G. , Pantelyat, Alexander , Pirio‐Richardson, Sarah, Roze, Emmanuel , Saunders‐Pullman, Rachel , Suchowersky, Oksana , Truong, Daniel , Morgante, Francesca , Adler, C H , Berardelli, Alfredo , Borsche, Max , Mahajan, Abhimanyu , Martino, Davide , Pantelyat, Alex , Sajobi, Tolulope T. , Berman, Brian D. , Espay, Alberto J. , Ferrazzano, Gina , Frank, Samuel , Hallett, Mark , Jankovic, Joseph J. , Malaty, Irene A. , Vidailhet, Marie , Shukla, Aparna Wagle , Perlmutter, Joel S. , Jinnah, H. A.

Mayo Clinic

European Journal of Neurology | July 22, 2021 | Volume: 28 | Issue: 12 | Pages: 3999-4009

10.1111/ene.15031 | PMID 34296504 Get It

AbstractBackground and purposeSeveral clinical and demographic factors relate to anatomic spread of adult‐onset isolated dystonia, but a predictive model is still lacking. The aims of this study were: (i) to develop and validate a predictive model of anatomic spread of adult‐onset isolated dystonia; and (ii) to evaluate whether presence of tremor associated with dystonia influences model predictions of spread.MethodsAdult‐onset isolated dystonia participants with focal onset from the Dystonia Coalition Natural History Project database were included. We developed two prediction models, one with dystonia as sole disease manifestation (“dystonia‐only”) and one accepting dystonia OR tremor in any body part as disease manifestations (“dystonia OR tremor”). Demographic and clinical predictors were selected based on previous evidence, clinical plausibility of association with spread, or both. We used logistic regressions and evaluated model discrimination and calibration. Internal validation was carried out based on bootstrapping.ResultsBoth predictive models showed an area under the curve of 0.65 (95% confidence intervals 0.62–0.70 and 0.62–0.69, respectively) and good calibration after internal validation. In both models, onset of dystonia in body regions other than the neck, older age, depression and history of neck trauma were predictors of spread.ConclusionsThis predictive modeling of spread in adult‐onset isolated dystonia based on accessible predictors (demographic and clinical) can be easily implemented to inform individuals’ risk of spread. Because tremor did not influence prediction of spread, our results support the argument that tremor is a part of the dystonia syndrome, and not an independent or coincidental disorder.
Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
Kelley, Robin Kate , Harris, William Proctor , Ikeda, Masafumi , Okusaka, Takuji , Kang, Yoon‐Koo , Qin, Shukui , Tai, David , Lim, Ho Yeong , Yong, Wei Peng , Cheng, Ann‐Lii , Gasbarrini, Antonio , Damian, Silvia , Bruix, Jordi , Bendell, Johanna C. , Kim, Tae‐You , He, Philip , Makowsky, Mallory, Negro, Alejandra , Gasbarrini, Antonio , Ikeda, Masafumi , Okusaka, Takuji , Kang, Yoon-Koo , Qin, Shukui , Tai, David W-M , Lim, Ho Yeong , Yong, Wei-Peng , Cheng, Ann-Lii , Damian, Silvia , Borad, Mitesh J , He, Philip , Kudo, Masatoshi , Abou-Alfa, Ghassan K , Bruix, Jordi , Sangro, Bruno , Yau, Thomas , Borad, Mitesh J. , Standifer, Nathan E. , Kudo, Masatoshi , Abou‐Alfa, Ghassan K.

Mayo Clinic

Journal of Clinical Oncology | July 22, 2021 | Volume: 39 | Issue: 27 | Pages: 2991-3001

10.1200/jco.20.03555 | PMID 34292792 Get It

PURPOSE This phase I/II study evaluated tremelimumab (anticytotoxic T-lymphocyte–associated antigen-4 monoclonal antibody) and durvalumab (antiprogrammed death ligand-1 monoclonal antibody) as monotherapies and in combination for patients with unresectable hepatocellular carcinoma (HCC), including a novel regimen featuring a single, priming dose of tremelimumab (ClinicalTrials.gov identifier: NCT02519348 ). PATIENTS AND METHODS Patients with HCC who had progressed on, were intolerant to, or refused sorafenib were randomly assigned to receive T300 + D (tremelimumab 300 mg plus durvalumab 1,500 mg [one dose each during the first cycle] followed by durvalumab 1,500 mg once every 4 weeks), durvalumab monotherapy (1,500 mg once every 4 weeks), tremelimumab monotherapy (750 mg once every 4 weeks [seven doses] and then once every 12 weeks), or T75 + D (tremelimumab 75 mg once every 4 weeks plus durvalumab 1,500 mg once every 4 weeks [four doses] followed by durvalumab 1,500 mg once every 4 weeks). Safety was the primary end point. Secondary end points included objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors v1.1 and overall survival; exploratory end points included circulating lymphocyte profiles. RESULTS A total of 332 patients were enrolled (T300 + D, n = 75; durvalumab, n = 104; tremelimumab, n = 69; and T75 + D, n = 84). Tolerability was acceptable across arms, with grade ≥ 3 treatment-related adverse events occurring in 37.8%, 20.8%, 43.5%, and 24.4%, respectively. Confirmed ORRs (95% CI) were 24.0% (14.9 to 35.3), 10.6% (5.4 to 18.1), 7.2% (2.4 to 16.1), and 9.5% (4.2 to 17.9), respectively. An early expansion of CD8+ lymphocytes was associated with response across arms, with highest proliferating CD8+ lymphocyte levels occurring in the T300 + D arm. The median (95% CI) overall survival was 18.7 (10.8 to 27.3), 13.6 (8.7 to 17.6), 15.1 (11.3 to 20.5), and 11.3 (8.4 to 15.0) months in the T300 + D, durvalumab, tremelimumab, and T75 + D arms, respectively. CONCLUSION All regimens were found to be tolerable and clinically active; however, the T300 + D regimen demonstrated the most encouraging benefit-risk profile. The unique pharmacodynamic activity and association with ORR of the T300 + D regimen further support its continued evaluation in HCC.
Risk of Late-Onset Breast Cancer in Genetically Predisposed Women
Boddicker, Nicholas , Weitzel, Jeffrey N. , Kraft, Peter , Nathanson, Katherine L. , Goldgar, David E. , Na, Jie , Huang, Hongyan , Larson, Nicole L. , Yussuf, Amal , Vachon, Celine M. , Taylor, Jack A. , Scott, Christopher E., Pesaran, Tina , Patel, Alpa V. , Ong, Irene M. , Martínez, Elena, Ma, Huiyan , Lindström, Sara , Hodge, James M. , Haiman, Christopher A. , Gaudet, Mia M. , Gao, Chi , LaDuca, Holly , Dolinsky, Jill S. , Carter, Brian D., Auer, Paul, Yadav, Siddhartha , Chen, Chen , Boddicker, Nicholas J , Hu, Chunling , Weitzel, Jeffrey N , Kraft, Peter , Nathanson, Katherine L , Goldgar, David E , Na, Jie , Gnanaolivu, Rohan D., Yussuf, Amal , Yao, Song , Vachon, Celine M. , Trentham-Dietz, Amy , Teras, Lauren R , Taylor, Jack A , Sandler, Dale P , Pesaran, Tina , Palmer, Julie R , Ong, Irene M , Neuhausen, Susan L. , Martı́nez, Marı́a Elena , Karam, Rachid , Hodge, James M , Gaudet, Mia M , Gao, Chi , LaDuca, Holly , Dolinsky, Jill S , Burnside, Elizabeth S , Bertrand, Kimberly A , Bernstein, Leslie , Ambrosone, Christine B , Yadav, Siddhartha , Hart, Steven N , Polley, Eric C , Domchek, Susan M , Couch, Fergus J. , Chen, C , Hu, Chunling , Gnanaolivu, Rohan , Yao, Song , Trentham‐Dietz, Amy , Teras, Lauren R. , Sandler, Dale P. , Palmer, Julie R. , Olson, Janet E. , O’Brien, Katie M. , Marchand, Loı̈c Le , Kooperberg, Charles , Karam, Rachid , Hunter, David J. , Lacey, James V. , Chao, Elizabeth , Burnside, Elizabeth S. , Bertrand, Kimberly A. , Bernstein, Leslie , Ambrosone, Christine B. , Hart, Steven N. , Polley, Eric C. , Domchek, Susan M. , Couch, Fergus J.

Mayo Clinic

Journal of Clinical Oncology | July 22, 2021 | Volume: 39 | Issue: 31 | Pages: 3430-3440

10.1200/jco.21.00531 | PMID 34292776 Get It

PURPOSE The prevalence of germline pathogenic variants (PVs) in established breast cancer predisposition genes in women in the general population over age 65 years is not well-defined. However, testing guidelines suggest that women diagnosed with breast cancer over age 65 years might have < 2.5% likelihood of a PV in a high-penetrance gene. This study aimed to establish the frequency of PVs and remaining risks of breast cancer for each gene in women over age 65 years. METHODS A total of 26,707 women over age 65 years from population-based studies (51.5% with breast cancer and 48.5% unaffected) were tested for PVs in germline predisposition gene. Frequencies of PVs and associations between PVs in each gene and breast cancer were assessed, and remaining lifetime breast cancer risks were estimated for non-Hispanic White women with PVs. RESULTS The frequency of PVs in predisposition genes was 3.18% for women with breast cancer and 1.48% for unaffected women over age 65 years. PVs in BRCA1, BRCA2, and PALB2 were found in 3.42% of women diagnosed with estrogen receptor (ER)–negative, 1.0% with ER-positive, and 3.01% with triple-negative breast cancer. Frequencies of PVs were lower among women with no first-degree relatives with breast cancer. PVs in CHEK2, PALB2, BRCA2, and BRCA1 were associated with increased risks (odds ratio = 2.9-4.0) of breast cancer. Remaining lifetime risks of breast cancer were ≥ 15% for those with PVs in BRCA1, BRCA2, and PALB2. CONCLUSION This study suggests that all women diagnosed with triple-negative breast cancer or ER-negative breast cancer should receive genetic testing and that women over age 65 years with BRCA1 and BRCA2 PVs and perhaps with PALB2 and CHEK2 PVs should be considered for magnetic resonance imaging screening.
DIA-Based Proteome Profiling of Nasopharyngeal Swabs from COVID-19 Patients
Vanderboom, Patrick M. , Madugundu, Anil K. , Garapati, Kishore , Peterson, Jane A., Saraswat, Mayank , Pandey, Akhilesh , Chavan, Sandip , Pandey, Akhilesh , Pandey, Akhilesh , Garapati, Kishore , Mun, Dong‐Gi , Peterson, Jane A.

Mayo Clinic

Journal of Proteome Research | July 22, 2021 | Volume: 20 | Issue: 8 | Pages: 4165-4175

10.1021/acs.jproteome.1c00506 | PMID 34292740 Get It

Surgical Angiogenesis of Decellularized Nerve Allografts Improves Early Functional Recovery in a Rat Sciatic Nerve Defect Model
Saffari, Tiam M. , Mathot, Femke , Friedrich, Patricia F. , Bishop, Allen T. , Shin, Alexander Y.

Mayo Clinic

Plastic & Reconstructive Surgery | July 22, 2021 | Volume: 148 | Issue: 3 | Pages: 561-570

10.1097/prs.0000000000008291 | PMID 34292916 Get It

Background: Surgical angiogenesis applied to nerve grafts has been suggested to enhance nerve regeneration after nerve injury. The authors hypothesized that surgical angiogenesis to decellularized nerve allografts would improve functional recovery in a rat sciatic nerve defect model. Methods: Sixty Lewis rats were divided in three groups of 20 animals each. Unilateral sciatic nerve defects were repaired with (1) autografts, (2) decellularized allografts, and (3) decellularized allografts wrapped with a superficial inferior epigastric artery fascial flap to add surgical angiogenesis. Twelve and 16 weeks after surgery, nerve regeneration was assessed using functional, electrophysiologic, histologic, and immunofluorescence analyses. Ultrasonography was used during the survival period to noninvasively evaluate muscle atrophy and reinnervation by measuring cross-sectional muscle area. Results: Surgical angiogenesis of allografts demonstrated significantly improved isometric tetanic force recovery at 12 weeks, compared to allograft alone, which normalized between groups at 16 weeks. Cross-sectional muscle areas showed no differences between groups. Electrophysiology showed superiority of autografts at both time points. No differences were found in histologic analysis, besides a significantly inferior N ratio in allografts at 12 weeks. Immunofluorescent expression of CD34, indicating vascularity, was significantly enhanced in the superficial inferior epigastric artery fascial group compared to allografts at 12 weeks, with highest expression at 16 weeks compared to all groups. Conclusion: Surgical angiogenesis with an adipofascial flap to the nerve allograft increases vascularity in the nerve graft, with subsequent improvement of early muscle force recovery, comparable to autografts.
Low-Dose Ketamine Infusion for Perioperative Pain Management in Patients Undergoing Laparoscopic Gastric Bypass: A Prospective Randomized Controlled Trial
Seman, Mitchell T. , Malan, Shawn H. , Butterfield, Richard , Harold, Kristi L., Madura, James A., Rosenfeld, David M. , Gorlin, Andrew , Gorlin, Andrew W, Buras, Matthew

Mayo Clinic

Anesthesiology Research and Practice | July 22, 2021 | Volume: 2021 | Issue: No issue available | Pages: 1-11

10.1155/2021/5520517 | PMID 34335740 Get It

Introduction. Obesity is a common comorbidity seen in the perioperative setting and is associated with many diseases including cardiovascular disease and obstructive sleep apnea. Laparoscopic Roux-en-Y gastric bypass is the gold standard surgical treatment for patients whose weight is refractory to diet and exercise. Caring for these patients perioperatively presents unique challenges to anesthesiologists and is associated with an increased risk of adverse respiratory events. In our study, we hypothesize that a low-dose perioperative ketamine infusion will reduce opioid consumption and improve analgesia when compared to standard therapy. Methods. This is a single-center, prospective randomized controlled study enrolling 35 patients in total. Patients were randomized equally into the ketamine and control group. Preop, intraop, and postop management regimens were standardized. The ketamine group received a 0.3 mg/kg ideal body weight ketamine bolus after induction followed by a 0.2 mg/kg/hr ketamine infusion continued into the postop setting for up to 24 hours. Data collected included total perioperative opioids used converted to oral morphine equivalents (ME), pain scores, side effects, hospital length of stay, and patient satisfaction captured via postoperative questionnaires. Results. The use of perioperative opioid consumption was significantly lower in the ketamine group when compared with the control group (179.9 ME versus 248.7 ME, P = 0.03 ). There was no statistically significant difference in pain scores or hospital length of stay postoperatively between the two groups. There were also no reported adverse respiratory events, prolonged sedation, agitation, or other side effects reported in either group. The patient satisfaction questionnaires showed a significant difference with the ketamine group reporting lower maximum pain scores, a decrease in how pain limited activities of daily living once discharged, and increased hospital pain management satisfaction scores. Conclusions. Perioperative low-dose ketamine infusions significantly reduced opioid consumption in morbidly obese patients undergoing laparoscopic gastric bypass surgery.
Extracorporeal Membrane Oxygenation in Patients With COVID-19
Abu‐Haniyeh, Ahmed , Li, Heyi , Kaul, Risheek , Aronow, Wilbert S. , Frishman, William H. , Lansman, Steven , Sreenivasan, Jayakumar , Ranka, Sagar , Lahan, Shubham , Malik, Aaqib H.

Mayo Clinic

Cardiology in Review | July 22, 2021 | Volume: 30 | Issue: 3 | Pages: 129-133

10.1097/crd.0000000000000410 | PMID 34292184 Get It

Coronavirus disease 2019 (COVID-19) is characterized by a clinical spectrum of diseases ranging from asymptomatic or mild cases to severe pneumonia with acute respiratory distress syndrome (ARDS) requiring mechanical ventilation. Extracorporeal membrane oxygenation (ECMO) has been used as rescue therapy in appropriate patients with COVID-19 complicated by ARDS refractory to mechanical ventilation. In this study, we review the indications, challenges, complications, and clinical outcomes of ECMO utilization in critically ill patients with COVID-19-related ARDS. Most of these patients required venovenous ECMO. Although the risk of mortality and complications is very high among patients with COVID-19 requiring ECMO, it is similar to that of non-COVID-19 patients with ARDS requiring ECMO. ECMO is a resource-intensive therapy, with an inherent risk of complications, which makes its availability limited and its use challenging in the midst of a pandemic. Well-maintained data registries, with timely reporting of outcomes and evidence-based clinical guidelines, are necessary for the careful allocation of resources and for the development of standardized utilization protocols.
Differential Activity of PARP Inhibitors in BRCA1 - Versus BRCA2 -Altered Metastatic Castration-Resistant Prostate Cancer
Taza, Fadi , Holler, Albert , Fu, Wei , Wang, Hao , Adra, Nabil , Albany, Costantine , Ashkar, Ryan, Cheng, Heather H. , Sokolova, Alexandra , Agarwal, Neeraj , Kessel, Adam , Bryce, Alan H. , Nafissi, Nellie , Berchuck, Jacob E. , Taplin, Mary‐Ellen , Aggarwal, Rahul , Vlachostergios, Panagiotis J. , Alva, Ajjai , Antonarakis, Emmanuel S. , Antonarakis, Emmanuel S. , Holler, Albert E , Sokolova, Alexandra O , Bryce, Alan H , Barata, Pedro , Sartor, A Oliver , Bastos, Diogo , Smaletz, Oren , Berchuck, Jacob E , Aggarwal, Rahul , Sternberg, Cora N , Vlachostergios, Panagiotis J , Su, Christopher , Marshall, Catherine H , Agarwal, Archana M , Cheng, Heather H , Antonarakis, Emmanuel S , Antonarakis, Emmanuel S , Wang, Hao , Barata, Pedro C. , Sartor, Oliver , Su, Christopher , Marshall, Catherine H.

Mayo Clinic

JCO Precision Oncology | July 22, 2021 | Volume: No volume available | Issue: 5 | Pages: 1200-1220

10.1200/po.21.00070 | PMID 34778690 Get It

PURPOSE Two poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and rucaparib) are US Food and Drug Administration–approved for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring BRCA1/ 2 mutations, but the relative efficacy of PARP inhibition in BRCA1- versus BRCA2-altered mCRPC is understudied. METHODS We conducted a multicenter retrospective analysis involving 12 sites. We collected genomic and clinical data from 123 patients with BRCA1/ 2-altered mCRPC who were treated with PARP inhibitors. The primary efficacy end point was the prostate-specific antigen (PSA) response (≥ 50% PSA decline) rate. Secondary end points were PSA progression-free survival (PSA-PFS), clinical or radiographic PFS, and overall survival. We compared clinical outcomes, and other genomic characteristics, among BRCA1- versus BRCA2-altered mCRPC. RESULTS A total of 123 patients (13 BRCA1 and 110 BRCA2) were included. PARP inhibitors used were olaparib (n = 116), rucaparib (n = 3), talazoparib (n = 2), and veliparib (n = 2). At diagnosis, 72% of patients had Gleason 8-10 disease. BRCA1 patients were more likely to have metastatic disease at presentation (69% v 37%; P = .04). Age, baseline PSA, metastatic distribution, and types of previous systemic therapies were similar between groups. There were equal proportions of germline mutations (51% v 46%; P = .78) in both groups. BRCA1 patients had more monoallelic (56% v 41%; P = .49) and concurrent TP53 (55% v 36%; P = .32) mutations. PSA 50 responses in BRCA1- versus BRCA2-altered patients were 23% versus 63%, respectively ( P = .01). BRCA2 patients achieved longer PSA-PFS (HR, 1.94; 95% CI, 0.92 to 4.09; P = .08), PFS (HR, 2.08; 95% CI, 0.99 to 4.40; P = .05), and overall survival (HR, 3.01; 95% CI, 1.32 to 6.83; P = .008). Biallelic (compared with monoallelic) mutations, truncating (compared with missense) mutations, and absence of a concurrent TP53 mutation were associated with PARP inhibitor sensitivity. CONCLUSION PARP inhibitor efficacy is diminished in BRCA1- versus BRCA2-altered mCRPC. This is not due to an imbalance in germline mutations but might be related to more monoallelic mutations and/or concurrent TP53 alterations in the BRCA1 group.
Incidence of Axillary Adenopathy in Breast Imaging After COVID-19 Vaccination
Robinson, Kristin A. , Gococo-Benore, Denise A. , Li, Zhuo , Advani, Pooja , Chumsri, Saranya , Advani, Pooja P, Maimone, Santo

Mayo Clinic

JAMA Oncology | July 22, 2021 | Volume: 7 | Issue: 9 | Pages: 1395

10.1001/jamaoncol.2021.3127 | PMID 34292295 Get It